Fmr LLC Raises Position in Esperion Therapeutics Inc (ESPR)

Fmr LLC increased its holdings in Esperion Therapeutics Inc (NASDAQ:ESPR) by 43.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 739,289 shares of the biopharmaceutical company’s stock after buying an additional 225,205 shares during the quarter. Fmr LLC owned about 2.76% of Esperion Therapeutics worth $34,007,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Advisor Group Inc. increased its holdings in Esperion Therapeutics by 44.4% in the 4th quarter. Advisor Group Inc. now owns 947 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 291 shares during the period. Rehmann Capital Advisory Group acquired a new stake in shares of Esperion Therapeutics during the 4th quarter worth approximately $97,000. Xact Kapitalforvaltning AB acquired a new stake in shares of Esperion Therapeutics during the 4th quarter worth approximately $200,000. SG Americas Securities LLC acquired a new stake in shares of Esperion Therapeutics during the 4th quarter worth approximately $203,000. Finally, Paloma Partners Management Co acquired a new stake in shares of Esperion Therapeutics during the 4th quarter worth approximately $207,000. Institutional investors own 99.84% of the company’s stock.

Esperion Therapeutics stock opened at $40.94 on Friday. Esperion Therapeutics Inc has a 1 year low of $33.06 and a 1 year high of $76.48.

A number of equities research analysts have recently commented on the stock. Northland Securities set a $65.00 price objective on shares of Esperion Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. BidaskClub raised shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, January 31st. Cowen reaffirmed a “buy” rating and set a $94.00 price objective on shares of Esperion Therapeutics in a research note on Tuesday, January 15th. Chardan Capital reaffirmed a “hold” rating and set a $50.00 price objective on shares of Esperion Therapeutics in a research note on Thursday, March 14th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $112.00 price objective on shares of Esperion Therapeutics in a research note on Friday, March 29th. Three investment analysts have rated the stock with a sell rating, four have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $73.69.

In related news, CEO Timothy M. Mayleben purchased 5,000 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The shares were purchased at an average price of $48.73 per share, with a total value of $243,650.00. Following the purchase, the chief executive officer now owns 51,163 shares of the company’s stock, valued at $2,493,172.99. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Richard Bartram sold 8,000 shares of Esperion Therapeutics stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $42.88, for a total transaction of $343,040.00. The disclosure for this sale can be found here. In the last three months, insiders purchased 65,000 shares of company stock worth $3,155,550 and sold 48,329 shares worth $2,280,206. 14.50% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/fmr-llc-raises-position-in-esperion-therapeutics-inc-espr.html.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Recommended Story: Is a Roth IRA right for you?

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.